نتایج جستجو برای: peginterferon

تعداد نتایج: 9316  

2015
Suheyla Komur Behice Kurtaran Ayse Seza Inal Husnu Pullukcu Aslihan Ulu Ferit Kuscu Tansu Yamazhan Yesim Tasova Hasan Salih Zeki Aksu

BACKGROUND In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1. OBJECTIVES In Turkey, telaprevir has been used since March 2013. We aimed to evaluate res...

2015
Shingo Nakamoto Fumio Imazeki Makoto Arai Shin Yasui Masato Nakamura Yuki Haga Reina Sasaki Tatsuo Kanda Hiroshi Shirasawa Osamu Yokosuka Johannes Haybaeck

We examined whether hepatitis C virus (HCV) genotype 1b core- and NS5A-region mutations are associated with response to peginterferon α-2b plus ribavirin combination therapy. A total of 103 patients with high HCV genotype 1b viral loads (≥ 100 KIU/mL) were treated with the combination therapy. Pretreatment mutations in the core region and interferon sensitivity determining region (ISDR) in the ...

Journal: :The Netherlands journal of medicine 2006
E H C J Buster H L A Janssen

The availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV ) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term. Treatment is generally recommended for patients with high serum HBV DNA and elevated ALAT, indicat...

Journal: :Annals of hepatology 2012
Jaber Al-Ali Iqbal Siddique Rosh Varghese Fuad Hasan

BACKGROUND Approximately one-third of patients with chronic hepatitis C virus infection have persistently normal liver enzymes reflected by a normal serum alanine transaminase (ALT). Data with regards the efficacy and safety of treatment in patients chronically infected with Hepatitis C virus genotype 4 and normal serum ALT are limited. AIM To evaluate the efficacy and safety of peginterferon...

Journal: :The Journal of infectious diseases 2009
Ming-Lung Yu Chuan-Mo Lee Wan-Long Chuang Sheng-Nan Lu Chia-Yen Dai Jee-Fu Huang Zu-Yau Lin Tsung-Hui Hu Chien-Hung Chen Chao-Hung Hung Jin-Houng Wang Chi-Ling Chen Jia-Horng Kao Ming-Yang Lai Chen-Hua Liu Tung-Hung Su Shun-Sheng Wu Li-Ying Liao Hsing-Tao Kuo You-Chen Chao Shui-Yi Tung Sien-Sing Yang Pei-Jer Chen Chun-Jen Liu Ding-Shinn Chen

BACKGROUND With use of peginterferon alfa-2a and ribavirin combination therapy in patients with dual chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 11.2% of patients achieved clearance of hepatitis B surface antigen (HBsAg) at 6 months after treatment; however, reactivation of HBV DNA was observed in 36.3%. We investigated the predictive potential of HBsAg quantification...

Journal: :Bangladesh Medical Research Council bulletin 2013
M Z Rahman D S Ahmed H Masud S Parveen M A Rahman M S Chowdhury R Barua S M Ishaque

Peginterferon alpha-2a and ribavirin combination therapy achieves a sustained virological response (SVR) in patients with chronic hepatitis C. Little is know about long-term durability of hepatitis C virus--Ribonucleic acid (HCV-RNA) negativity in patient treated with pegylated interferon and ribavirin therapy. Aim of this study was to evaluate the durability of virologic response in patients w...

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2009
Marcelo Cunio Machado Fonseca Gabriela Tannus Branco de Araújo Denizar Vianna Araújo

The treatment of chronic hepatitis C (CHC) with peginterferon alpha-2b/ribavirin (PegIFN + Rib) produced larger sustained viral response (SVR) compared to the conventional (non-pegylated) interferon/ribavirin (IFN + Rib), but its cost-effectiveness was not assessed in Brazil. We developed a Markov model to mirror the natural disease history and cohorts of patients with hepatitis C virus (HCV), ...

2016
Ming-Ying Lu Ching-I Huang Ming-Yen Hsieh Tusty-Juan Hsieh Edward Hsi Pei-Chien Tsai Yi-Shan Tsai Ching-Chih Lin Meng-Hsuan Hsieh Po-Cheng Liang Yi-Hung Lin Nai-Jen Hou Ming-Lun Yeh Chung-Feng Huang Zu-Yau Lin Shinn-Cherng Chen Jee-Fu Huang Wan-Long Chuang Chia-Yen Dai Ming-Lung Yu

Hepatitis C virus (HCV) can replicate in peripheral blood mononuclear cells (PBMCs), which can produce interferon to defend against virus infection. We hypothesized that dynamic gene expression in PBMCs might impact the treatment efficacy of peginterferon/ribavirin in HCV patients. PBMCs were collected at baseline, 1st week and 4th week of treatment from 27 chronic HCV-1 patients with 48-week p...

2011
Seyed Moayed Alavian Seyed Vahid Tabatabaei Bita Behnava Nastaran Mahboobi

BACKGROUND A head-to-head comparison of the 72-week and 48-week anti-HCV therapies in slow responders with genotype 1 infection has been performed in several randomized clinical trials (RCTs). OBJECTIVES This review aimed at summarizing and pooling the results of these studies. MATERIALS AND METHODS RCTs that had evaluated the 72-week vs. 48-week anti-HCV therapy (peginterferon and ribaviri...

2012
Mostafa Alavi Moghaddam Mohammad Reza Zali Seyed Hossein Aalaei Andabili Faramarz Derakhshan Seyed Mohammad Miri Seyed Moayed Alavian

BACKGROUND Hepatitis C is a major reason of morbidity and mortality among hemophilia patients. Although combination therapy with peginterferon (peg-INF) and ribavirin is considered as standard treatment for chronic hepatitis C (CHC), but more evidence of the efficacy and safety is needed. OBJECTIVES In this study, efficacy and tolerability of combination therapy with peginterferon α-2a-ribavi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید